Adaptive Biotechnologies opened lower at $27.36, compared with its previous close of $28.17. In the last trading session, the stock traded between $26.27 and $27.97. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Adaptive Biotechnologies is now worth
$ 79.07
resulting in a loss of
$ 20.93 (20.93%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-1.75 (-6.23%)
Day High
$27.97
Day Low
$26.27
Day Open
$27.36
Prev Close
$28.17
Volume
18,68,930
1W Return
8.26%
1M Return
-8.12%
3M Return
17.12%
6M Return
95.24%
1Y Return
57.24%
Market Cap ($ Mn)
4,216
PE Ratio
-
PB Ratio
28.04
PEG Ratio
-
ROE
-29.85%
ROCE
-13.61%
EPS (TTM)
$-0.25
1 Week
8.26%
1 Month
-8.12%
3 Months
17.12%
6 Months
95.24%
9 Months
43.80%
Adaptive Biotechnologies to report Q3 2026 results on November 4
Adaptive Biotechnologies Corp will report Q3 2026 financial results on November 4, 2026. Conference call scheduled for 1:30 pm Pacific Time / 4:30 pm Eastern Time. Webcast archive will be available for replay within 24 hours post-event.
15 days agoMorgan Stanley raises Adaptive Biotechnologies price target to $27
Morgan Stanley raised Adaptive Biotechnologies' price target from $22 to $27. The rating remains at Equal-Weight. Analyst Tejas Savant made the revision.
17 days agoAdaptive Biotech highlights MRD testing in new myeloma cure definition
New IMS/IMWG consensus defines myeloma cure as five years complete remission without treatment. Cure status requires four negative MRD tests using next-generation sequencing at 10⁻⁶ sensitivity. Adaptive Biotechnologies' clonoSEQ highlighted as key tool for meeting rigorous 1-in-1-million detection standard. Definition integrates advanced imaging (PET/CT or MRI) alongside molecular MRD assessment.
1mo agoNCCN guidelines name clonoSEQ for MRD assessment in myeloma
NCCN Guidelines add dedicated page MYEL-E for MRD testing principles. clonoSEQ named as FDA-cleared assay for MRD assessment. 10-6 sensitivity established as preferred standard for testing. Updates aim to standardize clinician approach to myeloma management.
1mo agoBTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25
BTIG analyst Mark Massaro maintains a Buy rating on Adaptive Biotechnologies (NASDAQ: ADPT). The firm raised its price target from $24 to $25, reflecting a sustained positive outlook on the company's equity performance and investment potential.
3mo agoAdaptive Biotechnologies Q2 Results: Adjusted EPS and Sales Both Beat Estimates
Adaptive Biotechnologies delivered a beat on both earnings and revenue in the second quarter, with adjusted loss per share of $(0.10) outperforming the $(0.13) consensus estimate by 23.08% and improving 41.18% year-over-year from $(0.17). Quarterly sales of $71.553 million exceeded the $65.886 million analyst estimate by 8.60%, representing a 21.53% increase over the prior-year period's $58.879 million.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $709.18 | +0.71% | $2,62,217.18M | 33.49 | |
| $236.98 | +1.24% | $1,66,722.78M | 38.52 | |
| $436.00 | +2.73% | $62,846.78M | - | |
| $181.15 | -0.18% | $51,071.44M | 30.34 | |
| $480.07 | +0.67% | $47,165.92M | 104.98 | |
| $575.98 | +2.32% | $45,376.28M | 39.00 | |
| $275.06 | -1.43% | $45,329.89M | 32.52 | |
| $290.06 | +0.44% | $43,799.06M | 40.22 | |
| $1,718.61 | +1.19% | $34,435.79M | 31.52 | |
| $368.16 | +2.20% | $29,857.78M | 27.72 | |
| $252.92 | +2.97% | $27,826.01M | 25.77 | |
| $185.31 | +1.49% | $24,867.86M | - |
An investment of $100 made 5 years ago in Adaptive Biotechnologies is now worth
$ 79.07
resulting in a loss of
$ 20.93 (20.93%)
Note: Past profits do not guarantee future returns.
